Aerovate Short Term Debt vs Non Current Liabilities Total Analysis

AVTE Stock

USD 2.44 0.02 0.83%

Aerovate Therapeutics financial indicator trend analysis is way more than just evaluating Aerovate Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aerovate Therapeutics is a good investment. Please check the relationship between Aerovate Therapeutics Short Term Debt and its Non Current Liabilities Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.

Short Term Debt vs Non Current Liabilities Total

Short Term Debt vs Non Current Liabilities Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aerovate Therapeutics Short Term Debt account and Non Current Liabilities Total. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Aerovate Therapeutics' Short Term Debt and Non Current Liabilities Total is -0.51. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of Aerovate Therapeutics, assuming nothing else is changed. The correlation between historical values of Aerovate Therapeutics' Short Term Debt and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Aerovate Therapeutics are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Short Term Debt i.e., Aerovate Therapeutics' Short Term Debt and Non Current Liabilities Total go up and down completely randomly.

Correlation Coefficient

-0.51

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Short Term Debt

Non Current Liabilities Total

Most indicators from Aerovate Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aerovate Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.At present, Aerovate Therapeutics' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 53.1 M, whereas Enterprise Value Multiple is projected to grow to (7.70).

	2022	2023	2024	2025 (projected)
Interest Income	1.8M	5.2M	5.9M	6.2M
Cost Of Revenue	68K	96K	110.4K	115.9K

Interest Income Cost Of Revenue

Aerovate Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Other Current Assets	Property Plant Equipment	Other Liab	Current Deferred Revenue	Non Currrent Assets Other	Other Assets	Non Current Liabilities Other
Total Assets		-0.83	0.67	0.71	1.0	0.96	-0.93	-0.8	0.87	0.94	-0.39	1.0	0.58	-0.79	0.92	0.34	1.0	1.0	1.0	0.87	0.98	0.76	-0.39	0.76	-0.75	0.76
Short Long Term Debt Total	-0.83		-0.68	-0.7	-0.8	-0.81	0.79	0.76	-0.76	-0.78	0.41	-0.83	-0.56	0.36	-0.8	-0.65	-0.8	-0.83	-0.82	-0.7	-0.82	-0.67	0.41	-0.67	0.68	-0.68
Other Current Liab	0.67	-0.68		1.0	0.63	0.83	-0.46	-0.96	0.81	0.5	-0.79	0.68	0.89	-0.63	0.9	0.73	0.63	0.67	0.63	0.39	0.72	0.84	-0.79	0.86	-0.9	0.88
Total Current Liabilities	0.71	-0.7	1.0		0.67	0.86	-0.5	-0.98	0.85	0.53	-0.78	0.72	0.88	-0.66	0.92	0.71	0.67	0.71	0.67	0.43	0.76	0.87	-0.78	0.89	-0.93	0.9
Total Stockholder Equity	1.0	-0.8	0.63	0.67		0.95	-0.94	-0.76	0.84	0.95	-0.37	1.0	0.53	-0.8	0.9	0.27	1.0	1.0	1.0	0.89	0.97	0.72	-0.37	0.73	-0.71	0.72
Net Tangible Assets	0.96	-0.81	0.83	0.86	0.95		-0.84	-0.91	0.9	0.86	-0.61	0.96	0.69	-0.82	0.99	0.42	0.95	0.96	0.94	0.79	0.95	0.83	-0.61	0.85	-0.87	0.85
Net Debt	-0.93	0.79	-0.46	-0.5	-0.94	-0.84		0.58	-0.62	-1.0	0.29	-0.93	-0.35	0.67	-0.78	-0.11	-0.94	-0.93	-0.95	-0.98	-0.85	-0.46	0.29	-0.47	0.48	-0.47
Retained Earnings	-0.8	0.76	-0.96	-0.98	-0.76	-0.91	0.58		-0.92	-0.61	0.64	-0.8	-0.81	0.7	-0.95	-0.7	-0.76	-0.79	-0.75	-0.49	-0.85	-0.92	0.64	-0.93	0.96	-0.95
Accounts Payable	0.87	-0.76	0.81	0.85	0.84	0.9	-0.62	-0.92		0.65	-0.43	0.87	0.72	-0.72	0.9	0.61	0.84	0.86	0.83	0.52	0.94	0.98	-0.43	0.97	-0.94	0.97
Cash	0.94	-0.78	0.5	0.53	0.95	0.86	-1.0	-0.61	0.65		-0.33	0.94	0.41	-0.7	0.8	0.13	0.95	0.94	0.96	0.98	0.87	0.49	-0.33	0.5	-0.5	0.5
Long Term Debt	-0.39	0.41	-0.79	-0.78	-0.37	-0.61	0.29	0.64	-0.43	-0.33		-0.39	-0.73	0.44	-0.67	-0.4	-0.37	-0.39	-0.37	-0.33	-0.36	-0.46	1.0	-0.53	0.62	-0.54
Cash And Short Term Investments	1.0	-0.83	0.68	0.72	1.0	0.96	-0.93	-0.8	0.87	0.94	-0.39		0.58	-0.79	0.92	0.34	1.0	1.0	1.0	0.87	0.98	0.76	-0.39	0.76	-0.75	0.76
Common Stock Shares Outstanding	0.58	-0.56	0.89	0.88	0.53	0.69	-0.35	-0.81	0.72	0.41	-0.73	0.58		-0.53	0.76	0.74	0.53	0.57	0.52	0.29	0.64	0.76	-0.73	0.74	-0.74	0.78
Non Current Liabilities Total	-0.79	0.36	-0.63	-0.66	-0.8	-0.82	0.67	0.7	-0.72	-0.7	0.44	-0.79	-0.53		-0.81	-0.03	-0.81	-0.79	-0.78	-0.65	-0.78	-0.67	0.44	-0.68	0.69	-0.68
Other Stockholder Equity	0.92	-0.8	0.9	0.92	0.9	0.99	-0.78	-0.95	0.9	0.8	-0.67	0.92	0.76	-0.81		0.5	0.9	0.92	0.9	0.72	0.92	0.85	-0.67	0.88	-0.9	0.88
Total Liab	0.34	-0.65	0.73	0.71	0.27	0.42	-0.11	-0.7	0.61	0.13	-0.4	0.34	0.74	-0.03	0.5		0.26	0.33	0.27	-0.02	0.44	0.68	-0.4	0.65	-0.63	0.67
Net Invested Capital	1.0	-0.8	0.63	0.67	1.0	0.95	-0.94	-0.76	0.84	0.95	-0.37	1.0	0.53	-0.81	0.9	0.26		1.0	1.0	0.89	0.97	0.72	-0.37	0.72	-0.71	0.72
Total Current Assets	1.0	-0.83	0.67	0.71	1.0	0.96	-0.93	-0.79	0.86	0.94	-0.39	1.0	0.57	-0.79	0.92	0.33	1.0		1.0	0.87	0.98	0.75	-0.39	0.75	-0.74	0.75
Net Working Capital	1.0	-0.82	0.63	0.67	1.0	0.94	-0.95	-0.75	0.83	0.96	-0.37	1.0	0.52	-0.78	0.9	0.27	1.0	1.0		0.9	0.97	0.71	-0.37	0.71	-0.7	0.71
Other Current Assets	0.87	-0.7	0.39	0.43	0.89	0.79	-0.98	-0.49	0.52	0.98	-0.33	0.87	0.29	-0.65	0.72	-0.02	0.89	0.87	0.9		0.77	0.35	-0.33	0.37	-0.39	0.37
Property Plant Equipment	0.98	-0.82	0.72	0.76	0.97	0.95	-0.85	-0.85	0.94	0.87	-0.36	0.98	0.64	-0.78	0.92	0.44	0.97	0.98	0.97	0.77		0.85	-0.36	0.84	-0.81	0.84
Other Liab	0.76	-0.67	0.84	0.87	0.72	0.83	-0.46	-0.92	0.98	0.49	-0.46	0.76	0.76	-0.67	0.85	0.68	0.72	0.75	0.71	0.35	0.85		-0.46	0.99	-0.96	0.99
Current Deferred Revenue	-0.39	0.41	-0.79	-0.78	-0.37	-0.61	0.29	0.64	-0.43	-0.33	1.0	-0.39	-0.73	0.44	-0.67	-0.4	-0.37	-0.39	-0.37	-0.33	-0.36	-0.46		-0.53	0.62	-0.54
Non Currrent Assets Other	0.76	-0.67	0.86	0.89	0.73	0.85	-0.47	-0.93	0.97	0.5	-0.53	0.76	0.74	-0.68	0.88	0.65	0.72	0.75	0.71	0.37	0.84	0.99	-0.53		-0.99	1.0
Other Assets	-0.75	0.68	-0.9	-0.93	-0.71	-0.87	0.48	0.96	-0.94	-0.5	0.62	-0.75	-0.74	0.69	-0.9	-0.63	-0.71	-0.74	-0.7	-0.39	-0.81	-0.96	0.62	-0.99		-0.99
Non Current Liabilities Other	0.76	-0.68	0.88	0.9	0.72	0.85	-0.47	-0.95	0.97	0.5	-0.54	0.76	0.78	-0.68	0.88	0.67	0.72	0.75	0.71	0.37	0.84	0.99	-0.54	1.0	-0.99

Click cells to compare fundamentals

Aerovate Therapeutics Account Relationship Matchups

Aerovate Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	4.7M	175.4M	135.3M	127.4M	146.5M	98.2M
Other Current Liab	1.2M	958K	4.4M	14.8M	17.0M	17.9M
Total Current Liabilities	1.8M	2.6M	7.8M	17.6M	20.3M	21.3M
Total Stockholder Equity	(13.3M)	172.4M	126.7M	109.5M	125.9M	86.2M
Property Plant And Equipment Net	39K	728K	1.2M	902K	1.0M	641.1K
Net Debt	(4.6M)	(53.6M)	(21.3M)	(22.8M)	(20.5M)	(21.6M)
Retained Earnings	(13.4M)	(36.4M)	(87.9M)	(163.4M)	(147.1M)	(139.7M)
Accounts Payable	612K	1.2M	2.6M	2.4M	2.8M	1.6M
Cash	4.6M	54.2M	22.4M	23.5M	27.0M	23.8M
Non Current Assets Total	39K	1.0M	3.8M	3.2M	3.7M	3.8M
Cash And Short Term Investments	4.6M	167.4M	129.2M	122.4M	140.8M	94.0M
Liabilities And Stockholders Equity	4.7M	175.4M	135.3M	127.4M	146.5M	98.2M
Non Current Liabilities Total	16.3M	395K	776K	325K	292.5K	277.9K
Other Stockholder Equity	(16.2M)	208.9M	215.1M	272.6M	313.5M	329.2M
Total Liab	18.1M	2.9M	8.6M	18.0M	20.7M	12.0M
Net Invested Capital	(13.3M)	172.4M	126.7M	109.5M	125.9M	86.7M
Property Plant And Equipment Gross	39K	728K	1.2M	902K	1.0M	641.1K
Total Current Assets	4.7M	174.3M	131.5M	124.2M	142.9M	96.4M
Net Working Capital	2.9M	171.8M	123.7M	106.6M	122.6M	89.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports:

How To Invest In Aerovate

Details

Is Aerovate Stock a good investment?

Details

What is Aerovate Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.

You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.99)

Return On Assets

(0.45)

Return On Equity

(0.75)

The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aerovate Short Term Debt vs Non Current Liabilities Total Analysis

Short Term Debt vs Non Current Liabilities Total

Short Term Debt vs Non Current Liabilities Total Correlation Analysis

Correlation Coefficient

Short Term Debt

Non Current Liabilities Total

Aerovate Therapeutics fundamental ratios Correlations

Aerovate Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aerovate Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab

Cash	- 1.0	Net Debt
Non Current Liabilities Other	- 0.99	Other Assets
Other Assets	- 0.99	Non Currrent Assets Other
Other Current Assets	- 0.98	Net Debt
Retained Earnings	- 0.98	Total Current Liabilities
Other Assets	- 0.96	Other Liab